Literature DB >> 15827213

Antibodies against equine herpesviruses and equine arteritis virus in Burchell's zebras (Equus burchelli ) from the Serengeti ecosystem.

Kerstin Borchers1, Harald Wiik, Kai Frölich, Hanns Ludwig, Marion L East.   

Abstract

A total of 51 sera from a migratory population of Burchell's zebras (Equus burchelli) were collected in the Serengeti National Park (Tanzania) between 1999 and 2001 to assess levels of exposure to equine herpesvirus types 1, 2, 4, 9 (EHV-1, -2, -4, -9), EHV-1 zebra isolate T965, and equine arteritis virus (EAV). Using virus-specific neutralizing antibody tests, seroprevalence was high for EHV-9 (60% of 45), moderate for EAV (24% of 51), and lower for the EHV-1-related zebra isolate (17% of 41), EHV-1 (14% of 49), and EHV-4 (2% of 50). No evidence for exposure to EHV-2 was found (0% of 51). The high level of exposure to EHV-9 is interesting because evidence of infection with this virus has not been previously described in any wild equine population. Although the epidemiology of EHV-9 in Burchell's zebras is presently unknown, our results suggest that in East Africa, this species may be a natural host of EHV-9, a neuropathogenic virus that was only recently isolated from captive Thomson's gazelles (Gazella thomsoni) in Japan. There is currently no evidence that EHV-9 induced mortality in Burchell's zebras in the Serengeti, but because of the reported virulence of this virus for more susceptible species such as Thomson's gazelles, viral transmission from infected zebras to ungulates may result in mortality.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15827213     DOI: 10.7589/0090-3558-41.1.80

Source DB:  PubMed          Journal:  J Wildl Dis        ISSN: 0090-3558            Impact factor:   1.535


  7 in total

1.  Experimental intranasal infection of equine herpesvirus 9 (EHV-9) in suckling hamsters: kinetics of viral transmission and inflammation in the nasal cavity and brain.

Authors:  Nagwan El-Habashi; El-Shaymaa El-Nahass; Hideto Fukushi; Daisuke Hibi; Hiroki Sakai; Vito Sasseville; Tokuma Yanai
Journal:  J Neurovirol       Date:  2010-05       Impact factor: 2.643

2.  Equine herpesvirus type 9 in giraffe with encephalitis.

Authors:  Samy Kasem; Souichi Yamada; Matti Kiupel; Mary Woodruff; Kenji Ohya; Hideto Fukushi
Journal:  Emerg Infect Dis       Date:  2008-12       Impact factor: 6.883

3.  Comprehensive Serology Based on a Peptide ELISA to Assess the Prevalence of Closely Related Equine Herpesviruses in Zoo and Wild Animals.

Authors:  Azza Abdelgawad; Robert Hermes; Armando Damiani; Benjamin Lamglait; Gábor Á Czirják; Marion East; Ortwin Aschenborn; Christian Wenker; Samy Kasem; Nikolaus Osterrieder; Alex D Greenwood
Journal:  PLoS One       Date:  2015-09-17       Impact factor: 3.240

4.  Effect of a single point mutation on equine herpes virus 9 (EHV-9) neuropathogenicity after intranasal inoculation in a hamster model.

Authors:  Asmaa G Saleh; Shehata I Anwar; Osama M Abas; Hoda A Abd-Ellatieff; Mohamed Nasr; Ibrahim Saleh; Hideto Fukushi; Tokuma Yanai
Journal:  J Vet Med Sci       Date:  2017-07-15       Impact factor: 1.267

5.  Physiological costs of infection: herpesvirus replication is linked to blood oxidative stress in equids.

Authors:  David Costantini; Peter A Seeber; Sanatana-Eirini Soilemetzidou; Walid Azab; Julia Bohner; Bayarbaatar Buuveibaatar; Gábor Á Czirják; Marion L East; Eva Maria Greunz; Petra Kaczensky; Benjamin Lamglait; Jörg Melzheimer; Kenneth Uiseb; Alix Ortega; Nikolaus Osterrieder; Ditte-Mari Sandgreen; Marie Simon; Chris Walzer; Alex D Greenwood
Journal:  Sci Rep       Date:  2018-07-09       Impact factor: 4.379

Review 6.  A Scoping Review of Viral Diseases in African Ungulates.

Authors:  Hendrik Swanepoel; Jan Crafford; Melvyn Quan
Journal:  Vet Sci       Date:  2021-01-22

7.  New hosts for equine herpesvirus 9.

Authors:  Mark D Schrenzel; Tammy A Tucker; Taryn A Donovan; Martin D M Busch; Annabel G Wise; Roger K Maes; Matti Kiupel
Journal:  Emerg Infect Dis       Date:  2008-10       Impact factor: 6.883

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.